Novartis AG ADR (NVS)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $303.12B
Last updated: Nov 17, 2026 at 11:06 AM ET
Novartis AG ADR (NVS) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Novartis AG ADR reported EPS of $2.46, above the $2.25 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
Analysts' consensus for the quarter ending Dec 31, 2026 is 11.8% above the $2.03 reported for the quarter ended Dec 31, 2025.
NVS's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
NVS Earnings Call
The latest NVS earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, NVS beat 27, missed 10 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $15.03B, up 4.7% from $14.36B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $2.46 | $2.25 | $2.22 - $2.26 | +9.33% | Beat | +9.3% | 3 | 1 up, 0 down | Oct 27, 2026 | $15.03B |
| Jun 30, 2026 | $2.41 | $2.20 | N/A | +9.55% | Beat | -0.4% | 2 | 1 up, 0 down | Jul 21, 2026 | $14.42B |
| Mar 31, 2026 | $1.65 | $1.65 | N/A | 0.00% | In line | -27.6% | 1 | 1 up, 0 down | Apr 28, 2026 | $13.52B |
| Dec 31, 2025 | $2.03 | $2.00 | $1.97 - $2.04 | +1.50% | Beat | +2.5% | 2 | 2 up, 0 down | Feb 4, 2026 | $13.33B |
| Sep 30, 2025 | $2.25 | $2.31 | $2.30 - $2.32 | -2.60% | Miss | +9.2% | 2 | 1 up, 1 down | Oct 28, 2025 | $14.36B |
| Sep 29, 2025 | $2.25 | $2.26 | N/A | -0.44% | Miss | +9.2% | N/A | N/A | Oct 28, 2025 | $14.36B |
| Jun 30, 2025 | $2.42 | $2.37 | $2.34 - $2.41 | +2.11% | Beat | +22.8% | 2 | 2 up, 0 down | Jul 17, 2025 | $14.84B |
| Mar 31, 2025 | $2.28 | $2.17 | $2.15 - $2.19 | +5.07% | Beat | +26.7% | 2 | 2 up, 0 down | Apr 29, 2025 | $13.62B |
| Dec 31, 2024 | $1.98 | $1.76 | $1.74 - $1.84 | +12.50% | Beat | +29.4% | 4 | 0 up, 2 down | Jan 31, 2025 | $13.56B |
| Sep 30, 2024 | $2.06 | $1.93 | $1.88 - $2.01 | +6.74% | Beat | +18.4% | 7 | 4 up, 0 down | Oct 29, 2024 | $13.17B |
| Jun 30, 2024 | $1.97 | $1.86 | $1.84 - $1.94 | +5.91% | Beat | +7.7% | 7 | 4 up, 0 down | Jul 18, 2024 | $12.87B |
| Mar 31, 2024 | $1.80 | $1.68 | $1.54 - $1.77 | +7.14% | Beat | +5.3% | 5 | 1 up, 0 down | Apr 23, 2024 | $12.12B |
| Dec 31, 2023 | $1.53 | $1.66 | $1.58 - $1.80 | -7.83% | Miss | +0.7% | 4 | 2 up, 0 down | Jan 31, 2024 | $11.78B |
| Sep 30, 2023 | $1.74 | $1.74 | N/A | 0.00% | In line | +10.1% | 3 | 0 up, 1 down | Oct 24, 2023 | $12.09B |
| Jun 30, 2023 | $1.83 | $1.76 | N/A | +3.98% | Beat | +17.3% | 4 | 1 up, 1 down | Jul 18, 2023 | $11.74B |
| Mar 31, 2023 | $1.71 | $1.53 | $1.52 - $1.59 | +11.76% | Beat | +17.1% | 4 | 1 up, 0 down | Apr 25, 2023 | $11.05B |
| Dec 31, 2022 | $1.52 | $1.43 | $1.40 - $1.54 | +6.29% | Beat | +8.6% | 5 | 2 up, 0 down | Feb 1, 2023 | $13.09B |
| Sep 30, 2022 | $1.58 | $1.62 | N/A | -2.47% | Miss | -7.6% | 5 | 1 up, 0 down | Oct 25, 2022 | $10.78B |
| Jun 30, 2022 | $1.56 | $1.54 | N/A | +1.30% | Beat | -6.0% | N/A | 0 up, 0 down | Jul 19, 2022 | $13.09B |
| Mar 31, 2022 | $1.46 | $1.51 | $1.41 - $1.53 | -3.31% | Miss | -3.9% | 5 | 2 up, 0 down | Apr 26, 2022 | $12.81B |
| Dec 31, 2021 | $1.40 | $1.41 | $1.36 - $1.45 | -0.71% | Miss | +4.5% | 6 | 1 up, 1 down | Feb 2, 2022 | $13.52B |
| Sep 30, 2021 | $1.71 | $1.66 | $1.62 - $1.70 | +3.01% | Beat | +12.5% | 7 | N/A | Oct 26, 2021 | $13.37B |
| Jun 30, 2021 | $1.66 | $1.49 | $1.46 - $1.57 | +11.41% | Beat | +22.1% | 5 | N/A | Jul 21, 2021 | $13.29B |
| Mar 31, 2021 | $1.52 | $1.62 | $1.52 - $1.69 | -6.17% | Miss | -2.6% | 5 | N/A | Apr 27, 2021 | $12.69B |
| Dec 31, 2020 | $1.34 | $1.39 | $1.31 - $1.41 | -3.60% | Miss | +1.5% | 4 | N/A | Jan 26, 2021 | $13.03B |
| Sep 30, 2020 | $1.52 | $1.45 | $1.39 - $1.48 | +4.83% | Beat | +7.8% | 5 | N/A | Oct 27, 2020 | $12.54B |
| Jun 30, 2020 | $1.36 | $1.33 | $1.25 - $1.43 | +2.26% | Beat | +1.5% | 6 | N/A | Jul 21, 2020 | $11.62B |
| Mar 31, 2020 | $1.56 | $1.36 | $1.31 - $1.41 | +14.71% | Beat | +28.9% | 6 | N/A | Apr 28, 2020 | $12.71B |
| Dec 31, 2019 | $1.32 | $1.31 | $1.15 - $1.34 | +0.76% | Beat | +5.6% | 6 | N/A | Jan 29, 2020 | $12.72B |
| Sep 30, 2019 | $1.41 | $1.35 | $1.30 - $1.41 | +4.44% | Beat | +6.8% | 7 | N/A | Oct 22, 2019 | $12.48B |
| Jun 30, 2019 | $1.34 | $1.23 | $1.19 - $1.27 | +8.94% | Beat | +3.9% | 7 | N/A | Jul 18, 2019 | $12.02B |
| Mar 31, 2019 | $1.21 | $1.21 | $1.15 - $1.25 | 0.00% | In line | -5.5% | 5 | N/A | Apr 24, 2019 | $11.46B |
| Dec 31, 2018 | $1.25 | $1.30 | $1.20 - $1.41 | -3.85% | Miss | +3.3% | 7 | N/A | Jan 30, 2019 | $13.66B |
| Sep 30, 2018 | $1.32 | $1.34 | $1.27 - $1.36 | -1.49% | Miss | +2.3% | 6 | N/A | Oct 18, 2018 | $11.39B |
| Jun 30, 2018 | $1.29 | $1.28 | $1.25 - $1.30 | +0.78% | Beat | +5.7% | 9 | N/A | Jul 18, 2018 | $11.65B |
| Mar 31, 2018 | $1.28 | $1.27 | $1.26 - $1.32 | +0.79% | Beat | +13.3% | 5 | N/A | Apr 19, 2018 | $11.16B |
| Dec 31, 2017 | $1.21 | $1.17 | $1.13 - $1.29 | +3.42% | Beat | +8.0% | 9 | N/A | Jan 24, 2018 | $13.16B |
| Sep 30, 2017 | $1.29 | $1.24 | $1.17 - $1.28 | +4.03% | Beat | +4.9% | 8 | N/A | Oct 24, 2017 | $12.69B |
| Jun 30, 2017 | $1.22 | $1.17 | $1.15 - $1.22 | +4.27% | Beat | -0.8% | 9 | N/A | Jul 18, 2017 | $12.49B |
| Mar 31, 2017 | $1.13 | $1.10 | N/A | +2.73% | Beat | -3.4% | N/A | N/A | Apr 25, 2017 | $11.79B |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $8.98, up 15.0% from the year before. It was $4.75 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $8.98 | +15.0% |
| Dec 31, 2024 | $7.81 | +14.7% |
| Dec 31, 2023 | $6.81 | +11.3% |
| Dec 31, 2022 | $6.12 | -2.7% |
| Dec 31, 2021 | $6.29 | +8.8% |
| Dec 31, 2020 | $5.78 | +9.5% |
| Dec 31, 2019 | $5.28 | +2.7% |
| Dec 31, 2018 | $5.14 | +6.0% |
| Dec 31, 2017 | $4.85 | +2.1% |
| Dec 31, 2016 | $4.75 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 11,000 words across 22 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 11,123 | 22 | |
| 2026Q2 | Jun 30, 2026 | 8,446 | 20 | |
| 2025Q4 | Dec 31, 2025 | 8,190 | 17 | |
| 2025Q3 | Sep 30, 2025 | 8,005 | 16 | |
| 2025Q2 | Jun 30, 2025 | 6,197 | 14 | |
| 2025Q1 | Mar 31, 2025 | 6,821 | 16 | |
| 2024Q4 | Dec 31, 2024 | 7,591 | 16 | |
| 2024Q3 | Sep 30, 2024 | 10,058 | 18 |
2026Q3 Earnings Call
Opening remarks
Vasant Narasimhan CEO Thank you, Sharon. Hi, everyone, and welcome to our Q3 earnings call. Let me briefly read the safe harbor statement before we begin. The information presented today contains forward-looking statements that involve known and unknown risks, uncertainties, and other factors. These may cause actual results to be materially different from any future results, performance, or achievements expressed or implied by these statements. For a description of some of these factors, please refer to the company's Form 20-F and its most recent quarterly results on Form 6-K, which were filed with and furnished to the U.S. Securities and Exchange Commission, respectively. And with that, I will hand over to Robert.
Robert Kowalski Executive Thank you, Isabella, and thanks, everybody, for joining today's call. If we could move to slide 4. So, in the quarter—hold on one second. We are just getting our slides moving here. In the quarter, Novartis delivered sales growth and core margin expansion. That supported an upgrade to our full-year 2026 bottom-line guidance. You can see sales were up 4% in constant currency. Core operating income was up 10%. Mukul will go into the numbers in more detail, but we also had good margin performance in the quarter. There were a number of important pipeline milestones, notably, of course, as you all know, the remibrutinib data. Repsido also received FDA approval; Pluvicto received important approvals in the U.S. and China for HSPC; pelabresib was also filed in Europe; and Delzota received FDA priority review for DMD44. Overall, this allowed us to increase our guidance, and we will go through that in a bit more detail on the call. So, moving to the next slide. Priority brands continue to perform well. In the quarter, they were up 29%. There was very strong performance across Kisqali, Kesimpta, Scemblix, and Leqvio. A solid quarter from Cosentyx. Pluvicto: we are still in the midst of launching in HSPC, so we have not seen that pick up yet, and we will talk more about that in a bit. Rhapsido also had a very strong performance in the quarter. Moving to slide 6. Kisqali grew 37%, and it continued to take market share. You can see that our EBC shares in both the U.S. and Germany are very stable and at a very healthy level. Now, turning to the U.S. first: 38% growth in the quarter, $3 billion year to date. We are the leader in EBC, and our NBRx share was up 3 points versus the prior quarter. Fifty-three percent of the patients now on Kisqali are from the exclusive population. In metastatic disease, we are continuing to grow our NBRx share in first line, which is now at 55%.
Frequently Asked Questions About NVS
Did NVS beat earnings estimates last quarter?
Yes. Novartis AG ADR reported EPS of $2.46 for the quarter ended Sep 30, 2026, above the $2.25 estimate, a 9.33% surprise.
What EPS do analysts expect from NVS next quarter?
The consensus EPS estimate for Novartis AG ADR for the quarter ending Dec 31, 2026 is $2.27 from 12 analysts, with estimates from $2.05 to $2.43.
How often does NVS beat earnings estimates?
Novartis AG ADR beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +3.06%.
NVS pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts